Posts by Conan

  • OC Oerlikon

    Oerlikon: ready to move on!

    Conan wrote:


    Helvea raises OC Oerlikon to accumulate.


    Slowly, but surely... and like always late... analysts are following the course!

  • SMI im Januar 2011

    Changes in the equity portfolio - Day II

    Conan wrote:


    ...Best performers of the day include the same three titles as yesterday:

    1. Transocean (+3.61%)

    2. Syngenta (+2.92%)

    3. Credit Suisse (+2.42%)


    I let you to check the worst performers :)

  • Logitech

    Morgan Stanley cuts Logitech to “Underweight”

    Morgan Stanley reduces Logitech price target to CHF16 (CHF18.5) and cuts its rating to “Underweight” (“Equal weight”). Morgan Stanley argues that Logitech’s growth will remain below the long-term target of 10% as the changing consumer preferences and the prevalence of “touching” are hampering the demand for peripherals.


    Slumped by the downgrade, Logitech currently trades at CHF17.14 – down 4.03%. SPI is down 0.26%.

  • OC Oerlikon

    Oerlikon: ready to move on!

    Conan wrote:


    Trading volume record

    4.47Mio Oerlikon shares were exchanged today, marking the highest trading volume in the post-recapitalization period - in fact, marking the highest trading volume ever as a result of the multiplication of number of outstanding shares during the recapitalization.


    After trading as high as CHF5.44, Oerlikon closed today up 4.30% at CHF5.34. In the first two sessions of 2011, Oerlikon increased 9% in total and quickly rebounded from the 2010 closing price of CHF4.90.

  • SMI im Januar 2011

    Changes in the equity portfolio

    original text published at:

    http://www.investmaid.com/view…ac12b42bea04b7f7904f#p703


    SMI closed today barely changed (+0.01%).

    However, individual SMI components demonstrated remarkably different daily performances.


    Worst performers of the day:

    1. Swatch (-3.07%) – best performer of 2010

    2. Nestle (-1.36%) – increased 9.1% in 2010 to become the most valuable company in Europe

    3. Richemont (-1.08%) – second best performer of 2010


    Best performers of the day:

    1. Syngenta (+3.46%) – one of the worst performers of 2010 with 5.9% annual decrease

    2. Credit Suisse (+3.13%) – second worst performer of 2010

    3. Transocean (+3.02%) – worst performer of 2010


    In the early days of the new year, investors are noticeably in a rush to modify their equity holdings. Winners of 2010, which now seems to be fairly priced if not overpriced, are being replaced by the losers of 2010.

  • Petroplus (PPHN)

    Re: Technical Indicators

    Conan wrote:



    4.Parabolic Stop & Reversal: Sell (20/12)

    5. MACD (26,12,9): Sell (29/12)


    The set is now completed.

  • OC Oerlikon

    Re: Oerlikon: ready to move on!

    Conan wrote:


    [adapated from the original text]

    UBS increases Oerlikon price target to CHF5 (CHF4.60)... this is the second price target increase of UBS in the last two months.


    Back-to-back price target increases continue for Oerlikon: there were no brokers with a price target above CHF5 two months ago, whereas today there is no broker with a price target below CHF5.

  • OC Oerlikon

    Oerlikon: ready to move on!

    [adapated from the original text]

    ...Oerlikon is consolidating its place above CHF5 as investors are opening positions to play for the H2 2010 results, expected to be back in black...


    Today’s announcement, concerning the first ThinFab orders for the solar division, is especially important...as excluding the solar division, Oerlikon would be profitable...


    ...considering the recent resilience of the share price to remain above CHF5 and improved investor interest in mid-cap industrials, Oerlikon shines out as an excellent value with 35% upside potential.


    Full text:

    http://www.investmaid.com/view…c6bba0a99859c494cff7#p634

  • Petroplus (PPHN)

    Re: Technical Indicators

    Conan wrote:



    4.Parabolic Stop & Reversal: Sell (20/12)

    5. MACD (26,12,9): still lagging behind (histogram at +0.14)

  • Petroplus (PPHN)

    Technical Indicators

    Conan wrote:


    Technical Indicators: Dec 16

    1. Stochastic Oscillator: Sell (9/12)

    2. RSI: Sell (15/12)

    3. Commodity Channel Index: Sell (16/12)

    4. Parabolic Stop & Reversal: close to a sell signal (SAR at 11.84)

    5. MACD (26,12,9): lagging behind due to the sharp price movements (histogram at +0.24)


    http://www.investmaid.com/view…8e99c57ddbd29944&start=40

  • Roche

    A controversial view on Roche & Novartis

    [adapted from the original text published at investmaid.com]

    At CET13:10, Roche trades at CHF141.5 (-0.49%) and Novartis trades at CHF57.6 (+7.46%, following the announcement of Alcon merger). Share price of Roche is only 2.46 times that of Novartis – this is a historical moment in terms of the valuation gap between the two archrivals. Market is unfairly discounting the strength of Roche’s late-stage product pipeline. In a rather fair valuation, Roche should be trading at Novartis multiple of 2.7x. Sooner or later, this valuation discount is set to close and it makes sense to prefer Roche over Novartis after this point.

  • Novartis

    A controversial view on Roche & Novartis

    [adapted from the original text published at investmaid.com]

    At CET13:10, Roche trades at CHF141.5 (-0.49%) and Novartis trades at CHF57.6 (+7.46%, following the announcement of Alcon merger). Share price of Roche is only 2.46 times that of Novartis – this is a historical moment in terms of the valuation gap between the two archrivals. Market is unfairly discounting the strength of Roche’s late-stage product pipeline. In a rather fair valuation, Roche should be trading at Novartis multiple of 2.7x. Sooner or later, this valuation discount is set to close and it makes sense to prefer Roche over Novartis after this point.

  • Logitech

    Logitech

    Barclays Capital starts Logitech at “Underweight” with a price target of CHF18....


    Put under pressure by Barclays’ investment research report, Logitech currently trades at 19.25 – down 1.13% in a slightly positive market (SPI +0.17%).

  • Roche

    Roche’s late-stage pipeline

    [adapted from the original text]

    Roche’s update on its late-stage pipeline is clearly a demonstration of its innovation strength in order to reassure investors on the sustainability of its R&D dependent business model. Investors, becoming more risk averse after the financial crisis, have recently developed a strong tendency to see Novartis (a healthcare holding with diversified business lines) as a safer bet and prefer it over Roche (comparatively a pure-play pharmaceutical company)....


    Based on yesterday’s closing figures, share price of Roche is only 2.61 times that of Novartis. This level (ROG:NOVN) is almost the five year low...